Anlotinib, toripalimab, and chemo before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted therapy (anlotinib), immunotherapy (toripalimab), and chemotherapy given before surgery for esophageal cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that has not spread to other organs and is stage II to IIIB.
- You have not had any prior treatment for esophageal cancer.
- You are in good overall health (able to do daily activities) and your major organs (heart, lungs, liver, kidneys, thyroid) are working well.
- You are willing to use effective birth control during the study and for 8 weeks after the last dose.
- You do not have other active cancers, serious infections, or conditions like uncontrolled high blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of three drugs (penpulimab, anlotinib, and chemotherapy) given before surgery to shrink esophageal cancer. It is for people with locally advanced cancer who have not had treatment before.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.